Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618093 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4HTR2AADAM17L3MBTL1 | |
| SCHEMBL6458723 | 0.77 | CA2 (0.38) | — | |
| SCHEMBL617887 | 0.76 | MEN1 (0.51) | CHRNB2CHRNA4HTR2ASIGMAR1RAB9A | |
| SCHEMBL617888 | 0.76 | MEN1 (0.51) | CHRNB2CHRNA4HTR2ASIGMAR1RAB9A | |
| SCHEMBL618860 | 0.73 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL618859 | 0.73 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL6255116 | 0.70 | CHRNB2 (0.56) | CHRNB2CHRNA4HTR2A | |
| SCHEMBL620443 | 0.70 | CHRNB2 (1.00) | CHRNB2CHRNA4RAB9A | |
| SCHEMBL6255110 | 0.70 | CHRNB2 (0.56) | CHRNB2CHRNA4HTR2A | |
| SCHEMBL620444 | 0.70 | CHRNB2 (1.00) | CHRNB2CHRNA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8778978-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580826-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2371818-B1 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1317267-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | Targacept, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1311265-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | Targacept, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 573/4885CHRNA4 1876/4885HTR2A 1033/4885 |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885HTR2A 964/4885 |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885HTR2A 219/4885 |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885HTR2A 964/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885HTR2A 120/4885 |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CHRNB2 573/4885CHRNA4 1876/4885HTR2A 1033/4885 |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885HTR2A 964/4885 |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | CHRNB2 3/4885CHRNA4 21/4885HTR2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.